Company Announcements:
(reported by the Company)
No items found
Elevator Pitch:

Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases.

Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).

Opthea is currently investigating OPT-302 in an ongoing Phase 1/2A clinical trial in wet AMD patients.

Category: Health & biotech
URL: http://www.opthea.com/
Operational Status: Active
ASX Listing Code (if applicable): OPT
Year of Commencement: 2012

Level 1, 10 Wallace Avenue, Toorak, Melbourne, VIC 3142, AU

State: Victoria
Overseas Operations: No
Linkedin: https://www.linkedin.com/company/opthea/
Key Personnel:
Awards won: